公开(公告)号：US20160122324A1

公开(公告)日：2016-05-05

申请号：US14994710

申请日：2016-01-13

Applicant: Novartis AG

Inventor： Shenlin Huang ,  Xianming Jin ,  Zuosheng Liu ,  Daniel Poon ,  John Tellew ,  Yongqin Wan ,  Xing Wang ,  Yongping Xie

IPC: C07D403/04

CPC classification number: C07D403/04 ,  A61K9/0053 ,  A61K31/4184 ,  A61K31/506 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  A61K2300/00

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

公开(公告)号：US09314464B2

公开(公告)日：2016-04-19

申请号：US13931111

申请日：2013-06-28

Applicant: Novartis AG

Inventor： Shenlin Huang ,  Xianming Jin ,  Zuosheng Liu ,  Daniel Poon ,  John Tellew ,  Yongqin Wan ,  Xing Wang ,  Yongping Xie

IPC: A61K31/535 ,  A61K31/506 ,  C07D401/14 ,  C07D403/04 ,  A61K45/06 ,  C07D405/14

CPC classification number: C07D403/04 ,  A61K9/0053 ,  A61K31/4184 ,  A61K31/506 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  A61K2300/00

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.